Ding Yuan, Cheng Ming, Cao Bingyan, Liu Min, Hu Xuyun, Wu Di
Department of Endocrinology, Genetics, Metabolism, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, China.
Ministry of Education (MOE) Key Laboratory of Major Diseases in Children, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Front Endocrinol (Lausanne). 2025 Jan 27;15:1491825. doi: 10.3389/fendo.2024.1491825. eCollection 2024.
Apparent Mineralocorticoid Excess (AME) is a rare autosomal recessive disorder, characterized by a notably complex diagnostic process. To date, the majority of documented cases have been presented as individual case reports. This article aims to enhance the understanding of the course and prognosis of AME, by detailing the management protocols employed for patients with genetically confirmed diagnoses.
An analysis comprising three cases and a review of relevant literature were conducted to synthesize the insights and experiences derived from gathering clinical and laboratory data on patients.
All three patients were born to non-consanguineous parents, were small for gestational age and exhibited severe hypokalemia, metabolic alkalosis, hypertension, nephrocalcinosis, and hypercalciuria. The glomerular filtration rate was normal in all cases. One patient experienced complications related to hypertension. Genetic analysis revealed biallelic recessive variations in the gene in all three patients. Treatment with oral spironolactone and potassium chloride resulted in the normalization of both blood pressure and serum potassium levels in all patients.
This study presents the diagnostic and treatment experiences of three Chinese pediatric patients with AME type I. Through our analysis, four novel variants of the gene were identified, thereby enhancing the genotype-phenotype spectrum associated with AME. Early genetic testing in patients suspected of having AME is beneficial for facilitating prompt diagnosis and the implementation of standardized treatment protocols. Such measures are essential for the prevention or mitigation of target organ damage, as well as for the reduction of associated morbidity and mortality.
表观盐皮质激素过多症(AME)是一种罕见的常染色体隐性疾病,其诊断过程异常复杂。迄今为止,大多数已记录的病例都是以个案报告的形式呈现。本文旨在通过详细介绍对基因确诊患者所采用的管理方案,加深对AME病程和预后的理解。
对三例病例进行分析并回顾相关文献,以综合从收集患者临床和实验室数据中获得的见解和经验。
所有三名患者均为非近亲父母所生,均为小于胎龄儿,并表现出严重低钾血症、代谢性碱中毒、高血压、肾钙质沉着症和高钙尿症。所有病例的肾小球滤过率均正常。一名患者出现了与高血压相关的并发症。基因分析显示所有三名患者的该基因均存在双等位基因隐性变异。口服螺内酯和氯化钾治疗使所有患者的血压和血钾水平均恢复正常。
本研究介绍了三名中国儿科I型AME患者的诊断和治疗经验。通过我们的分析,鉴定出该基因的四个新变异,从而拓宽了与AME相关的基因型-表型谱。对疑似患有AME的患者进行早期基因检测有助于快速诊断并实施标准化治疗方案。这些措施对于预防或减轻靶器官损害以及降低相关发病率和死亡率至关重要。